ROSEN, A TIER-TIER FIRM, Encourages Investors in Fulgent Genetics, Inc. With Losses to Secure… | New

NEW YORK, Nov. 06, 2022 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds buyers of Fulgent Genetics, Inc. (NASDAQ: FLGT) securities between March 22, 2019 and August 4, 2022, both dates inclusive (the “Class Period”), the important deadline of November 21, 2022 for the main plaintiff.

THEN: If you purchased Fulgent Genetics securities during the Class Period, you may be entitled to compensation without payment of disbursements or fees through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Fulgent Genetics class action lawsuit, go to https://rosenlegal.com/submit-form/?case_id=8809 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for class action information. A class action lawsuit has already been filed. If you wish to act as a lead plaintiff, you must move the Court by November 21, 2022. A lead plaintiff is a representative party acting on behalf of other class members to direct litigation.

WHY ROSEN LAW: We encourage investors to select qualified lawyers with proven track records in leadership roles. Often, companies issuing reviews do not have comparable experience, resources, or significant peer recognition. Many of these firms do not actually handle securities class action lawsuits, but are merely middlemen who refer clients or partner with law firms that actually litigate the cases. Be wise in choosing lawyers. Rosen Law Firm represents investors worldwide, focusing its practice on securities class action and shareholder derivative litigation. Rosen Law Firm has reached the largest securities class action settlement against a Chinese company. Rosen Law Firm was ranked #1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017. The firm has ranked in the top 4 every year since 2013 and has recovered hundreds of million dollars for investors. In 2019 alone, the company secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s lawyers have been recognized by Lawdragon and Super Lawyers.

CASE DETAILS: According to the lawsuit, throughout the Class Period, the Defendants made false and/or misleading statements and/or failed to disclose that: (1) Fulgent Genetics conducted medically unnecessary lab, engaging in improper billing practices in connection with lab testing, and providing or receiving compensation in violation of anti-kickback law (which prohibits the knowing and willful payment of “compensation” for induce or reward the referral of patients or the generation of business involving any item or service payable by the federal government). health care programs) and the federal Stark Act (which prohibits a physician from making referrals for certain designated health services, including laboratory services, which are covered by the Medicare program, to an entity with which the physician or an immediate family member has a direct or indirect financial relationship); (2) as a result, Fulgent Genetics was subject to heightened legal and regulatory scrutiny; (3) Fulgent Genetics’ revenues, to the extent that they were derived from the aforementioned unlawful conduct, were unsustainable; (4) the foregoing, when disclosed, was likely to subject Fulgent Genetics to significant financial and/or reputational harm; and (5) therefore, the defendants’ public statements were materially false and misleading at all relevant times. When the real details entered the market, the lawsuit claims investors suffered damages.

To join the Fulgent Genetics class action lawsuit, go to https://rosenlegal.com/submit-form/?case_id=8809 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for class action information.

No class has been certified. Until a class is certified, you are not represented by an attorney unless you retain one. You can choose the lawyer of your choice. You can also remain an absent party member and do nothing at this point. An investor’s ability to participate in any potential future recovery does not depend on their status as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Lawyer advertisement. Previous results do not guarantee a similar result.

Contact information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, Pennsylvania

275 Madison Avenue, 40th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

[email protected]

[email protected]

[email protected]

www.rosenlegal.com

Copyright 2022 GlobeNewswire, Inc.

Denise W. Whigham